Business Description

US Stem Cell Inc
NAICS : 325414
SIC : 8731
ISIN : US90350U1007
Description
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Equity-to-Asset | -216.84 | |||||
Debt-to-Equity | -0.61 | |||||
Debt-to-EBITDA | -4.13 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -3285.36 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 17 | |||||
3-Year FCF Growth Rate | 30.7 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 99.85 | |||||
9-Day RSI | 85.34 | |||||
14-Day RSI | 51.85 | |||||
6-1 Month Momentum % | -95.89 | |||||
12-1 Month Momentum % | -96.72 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Days Inventory | 15.21 | |||||
Days Sales Outstanding | 18.7 | |||||
Days Payable | 23092.33 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -14.9 | |||||
Shareholder Yield % | -28.73 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 70.73 | |||||
Operating Margin % | -2098.78 | |||||
Net Margin % | -3485.37 | |||||
ROA % | -2835.32 | |||||
ROIC % | -20.73 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -4.21 | |||||
EV-to-EBITDA | -4.21 | |||||
EV-to-Revenue | 111.39 | |||||
EV-to-FCF | -29.95 | |||||
Earnings Yield (Greenblatt) % | -23.75 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:USRM
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
US Stem Cell Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0.082 | ||
EPS (TTM) ($) | -0.004 | ||
Beta | -0.88 | ||
Volatility % | 100.45 | ||
14-Day RSI | 51.85 | ||
14-Day ATR ($) | 0.000019 | ||
20-Day SMA ($) | 0.000235 | ||
12-1 Month Momentum % | -96.72 | ||
52-Week Range ($) | 0.0002 - 0.0068 | ||
Shares Outstanding (Mil) | 641.51 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
US Stem Cell Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
US Stem Cell Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
US Stem Cell Inc Frequently Asked Questions
What is US Stem Cell Inc(USRM)'s stock price today?
The current price of USRM is $0.00. The 52 week high of USRM is $0.01 and 52 week low is $0.00.
When is next earnings date of US Stem Cell Inc(USRM)?
The next earnings date of US Stem Cell Inc(USRM) is .
Does US Stem Cell Inc(USRM) pay dividends? If so, how much?
US Stem Cell Inc(USRM) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |